IRIS
RUBAGOTTI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.165
AS - Asia 1.914
NA - Nord America 1.258
Continente sconosciuto - Info sul continente non disponibili 265
SA - Sud America 150
AF - Africa 35
OC - Oceania 1
Totale 22.788
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 18.832
US - Stati Uniti d'America 1.159
SG - Singapore 838
CN - Cina 523
VN - Vietnam 245
FR - Francia 158
BD - Bangladesh 137
BR - Brasile 94
HK - Hong Kong 67
FI - Finlandia 43
CA - Canada 33
DE - Germania 33
JP - Giappone 31
AR - Argentina 28
CH - Svizzera 24
MX - Messico 23
GB - Regno Unito 18
NL - Olanda 13
IQ - Iraq 12
ES - Italia 11
CO - Colombia 10
ID - Indonesia 10
JM - Giamaica 9
RU - Federazione Russa 9
HN - Honduras 8
MA - Marocco 8
CR - Costa Rica 7
GT - Guatemala 7
PH - Filippine 7
PL - Polonia 6
VE - Venezuela 6
ZA - Sudafrica 5
AZ - Azerbaigian 4
DZ - Algeria 4
EC - Ecuador 4
IE - Irlanda 4
IN - India 4
KE - Kenya 4
PK - Pakistan 4
SA - Arabia Saudita 4
TH - Thailandia 4
JO - Giordania 3
NI - Nicaragua 3
SE - Svezia 3
TN - Tunisia 3
UY - Uruguay 3
CL - Cile 2
DO - Repubblica Dominicana 2
KW - Kuwait 2
NP - Nepal 2
OM - Oman 2
PY - Paraguay 2
RE - Reunion 2
SC - Seychelles 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TR - Turchia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
LT - Lituania 1
LV - Lettonia 1
LY - Libia 1
MM - Myanmar 1
NG - Nigeria 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
UZ - Uzbekistan 1
YE - Yemen 1
Totale 22.523
Salva come PNG Salva come JPEG
Città #
Genova 12.100
Genoa 3.768
Rapallo 1.634
Vado Ligure 1.189
Singapore 411
San Jose 309
Lauterbourg 156
Ashburn 114
Ho Chi Minh City 68
Hanoi 67
Hong Kong 65
Beijing 62
New York 53
Helsinki 43
Santa Clara 36
Bordighera 30
Tokyo 27
Frankfurt am Main 24
Zurich 24
Los Angeles 20
Dallas 18
Chicago 14
Council Bluffs 14
Rome 14
Milan 13
Tianjin 13
Mexico City 12
Philadelphia 12
Haiphong 11
Atlanta 10
Naples 9
Phoenix 9
Biên Hòa 8
Detroit 8
Orem 8
Amsterdam 7
Charlotte 7
Las Vegas 7
Queens 7
São Paulo 7
Toronto 7
Cleveland 6
Guatemala City 6
Kingston 6
Miami 6
Montreal 6
Newark 6
San José 6
Brooklyn 5
Buffalo 5
City of London 5
Jakarta 5
Rio de Janeiro 5
Shanghai 5
The Bronx 5
Arroyo Grande 4
Boston 4
Bourbonnais 4
Can Tho 4
Chula Vista 4
Cincinnati 4
Curitiba 4
Des Moines 4
Garland 4
Guangzhou 4
Houston 4
Hải Dương 4
Kunming 4
Lincoln 4
London 4
Louisville 4
Marietta 4
Milwaukee 4
Portland 4
Quảng Ngãi 4
San Pedro Sula 4
Springfield 4
Vĩnh Long 4
Amman 3
Baghdad 3
Bari 3
Beloit 3
Boardman 3
Columbus 3
Da Nang 3
Decatur 3
Dhaka 3
Dublin 3
Florence 3
Managua 3
Marrakesh 3
Montevideo 3
Ottawa 3
Palermo 3
Porto Alegre 3
Princeton 3
Seattle 3
Secaucus 3
Shenzhen 3
Stockholm 3
Totale 20.650
Salva come PNG Salva come JPEG
Nome #
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 309
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 257
Adjuvant immunochemotherapy in colorectal cancer Dukes C. 209
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 209
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 204
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. 197
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 197
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 189
"Autologous Bone Marrow Transplantation for Adult Advanced Stage Lymphoblastic Lymphoma in First CR. A Study of the NHLCSG". 186
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 185
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 185
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 185
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. 184
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 183
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 183
Differential expression of nuclear lamins in normal and cancerous prostate tissues 180
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 175
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 172
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 171
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 170
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 170
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 169
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 166
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 166
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 165
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 165
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 165
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 164
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 163
84: [Antibiotic preparation in operations on the large intestine. Experimental study] GF, Rollandi GA. 162
48: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. 161
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 161
A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients. 159
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. 159
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 159
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 156
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 156
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 154
Switching to aromatase inhibitors in early breast cancer. 153
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 153
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 152
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study 152
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 152
An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients 149
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 148
Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. 146
Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. 146
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. 146
VACOP-B Versus VACOP-B Plus Autologous Bone Marrow Transplantation for Advanced Diffuse Non-Hodgkin's Lymphoma: Results of a Prospective Randomized Trial by the Non-Hodgkin's Lymphoma Cooperative Study Group 146
Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. 146
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 146
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen. Results of the GROCTA trial. 145
Chemotherapy (CT) versus tamoxifen (T) versus chemoterapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial 145
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer 144
Carboplatin, Doxorubicin, and Cyclophosphamide Versus Cisplatin, Doxorubicin, and Cyclophosphamide: a Randomized Trial in Stage III-IV Epithelial Ovarian Carcinoma" 142
Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. 142
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 142
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study. 142
A. Lettera a: Journal of Clinical Oncology, 1987; 5, N. 4. 141
The impact of received dose intensity on the outcome of advanced ovarian cancer. 141
Chemoradiotherapy in locally advanced bladder cancer: neoadjuvant and definitive treatment 141
O-4 Ovarian suppression (OS) and tamoxifen (TAM) as an alternative to chemotherapy in early breast cancer. Long-term results of the GROCTA02 trial 141
Fattibilità della Terapia Adiuvante Intraperitoneale e Sistemica in Pazienti Operati Radicalmente per Carcinoma del Colon. 140
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. 140
Randomized cooperative study of perioperative chemotherapy in breast cancer. 140
Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial 139
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. 137
A Randomized Study in Metastatic Breast Cancer (MBC) Comparing Conventional Chemotherapy Vs Chemotherapy with Estrogenic Recruitment." 137
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials 137
Safety of antiandrogen therapy for treating prostate cancer. 136
A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy. 135
The prognostic value of stromal and epithelial periostin expression in human breast cancer: Correlation with clinical pathological features and mortality outcome 134
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. 133
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. 132
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. 132
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial 132
Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: a FONICAP randomized study. 132
D-TRP-6 LH-RH treatment of prostatic cancer. 132
Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. 132
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. 131
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study 131
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group 131
Gynaecomastia: the anastrozole paradox 131
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial 129
Insights from a long-term follow-up evaluation of early breast cancer (BC) outcomes by tumor subtype (TS) 128
Randomized trial of chemoimmunotherapy in advanced non-oat-cell lung cancer. 127
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. 126
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). 125
Prednisone plus Gefitinib (pG) versus prednisone plus placebo (ppl) in the treatment of hormone-refractory prostate cancer (HRPC). A randomized phase II trial. 124
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. 124
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 124
Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients 124
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 124
Stimulation of human breast cancer in vivo. Experimental findings and clinical results. 123
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 122
Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast. 122
Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. 122
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. 121
High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow. 1999 Apr;33(3-4):321-30 120
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. 119
Totale 15.279
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.603
article - articoli 69.511
book - libri 0
conference - conferenze 302
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.790
Totale 149.206
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.048 47 135 131 261 75 153 74 548 112 188 53 271
2022/20231.941 194 105 23 202 364 399 1 142 340 9 134 28
2023/2024898 48 143 16 99 90 154 54 64 35 29 53 113
2024/20252.741 53 235 89 194 422 290 263 427 103 110 228 327
2025/20264.349 484 114 226 313 600 509 784 221 243 409 267 179
2026/2027496 496 0 0 0 0 0 0 0 0 0 0 0
Totale 22.788